The evidence for admissions was of very low quality and showed a clinical reduction for both. Mortality did not demonstrate a clear effect with the confidence interval ranging from a decrease and increase in all-cause mortality .Very low quality evidence for quality of life also showed a clinical benefit for the intervention. Self-reported taking of prescribed medication showed no clinical difference and was of low quality. An automated measure of taking prescribed medication, however, showed a clinically important increase; the evidence of which was of very low quality. Case management Two studies with a long, non-specialist case management approach for a low risk HF population were included in this category (n=149 and n=190). The evidence for mortality was of very low quality and did not demonstrate a clear effect with the confidence interval ranging from a decrease and increase in all-cause mortality. One study (n=149) reported two medication outcomes: prescribed ACE- inhibitors at target dose and prescribed beta-blocker at target dose, both of which were of very low quality. The former outcome showed clinical harm for case management while the latter showed no difference. The second study (n=190) also reported a few other outcomes such as hospitalisations, which was of very low quality showing clinical harm for case management. This study also reported quality of life using the Kansas City Cardiomyopathy Questionnaire (very low quality showing clinical benefit for case management) and the SF-36 mental and physical components (low quality evidence demonstrating no difference for both). This study also reported prescribed double therapy of ACE- I/ARB and B-blocker which was of low quality evidence showing no difference between the interventions. Economic One cost-utility analysis found that mid-length intervention MDT clinic dominates (more effective and less costly) usual care in people with heart failure who are high risk. 